Evidence map›Paper›PMID 36257408›Full record

ArticleThe Journal of biological chemistry2022

Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition.

Laura M Haynes, Zachary M Huttinger, Andrew Yee, Colin A Kretz, David R Siemieniak, Daniel A Lawrence, David Ginsburg

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Venous thromboembolic disease genetics: from variants to function.Journal of thrombosis and haemostasis : JTH · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Laura M HaynesLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA.
Zachary M HuttingerLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA; Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Andrew YeeDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Colin A KretzDepartment of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
David R SiemieniakLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA; Howard Hughes Medical Institute.
Daniel A LawrenceDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
David GinsburgLife Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA; Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, Michigan, USA; Howard Hughes Medical Institute; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA; Departments of Human Genetics and Pediatrics, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: ginsburg@umich.edu.
University of Michigan · USHoward Hughes Medical Institute · USBaylor College of Medicine · USThrombosis and Atherosclerosis Research Institute · CA

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Unraveling the role of tPA in the neurovascular unitR01HL055374 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti, Daniel A Lawrence · 1995 to 2026
$8.6M
The Molecular Genetics of HemostasisR35HL135793 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GINSBURG, DAVID · 2017 to 2023
$4.1M
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease NeuropathologyR01AG074552 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAWRENCE, DANIEL A, MURPHY, GEOFFREY G · 2021 to 2025
$3.4M
Molecular Studies of Hemolytic ThrombosisR01HL154688 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI CRUZ, MIGUEL ANGEL, YEE, ANDREW · 2021 to 2024
$2.0M
Training Program in Translational Cardiovascular Research and EntrepreneurshipT32HL125242 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MICHELE, DANIEL E · 2015 to 2024
$1.9M
Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL055374NHLBI NIH HHS R01 HL154688NHLBI NIH HHS R35 HL135793NHLBI NIH HHS T32 HL125242NIA NIH HHS R01 AG074552NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor superfamily of proteins, is unique among serine protease inhibitors for exhibiting a spontaneous conformational change to a latent or inactive state. The functional half-life for this transition at physiologic temperature and pH is ∼1 to 2 h. To better understand the molecular mechanisms underlying this transition, we now report on the analysis of a comprehensive PAI-1 variant library expressed on filamentous phage and selected for functional stability after 48 h at 37 °C. Of the 7201 possible single amino acid substitutions in PAI-1, we identified 439 that increased the functional stability of PAI-1 beyond that of the WT protein. We also found 1549 single amino acid substitutions that retained inhibitory activity toward the canonical target protease of PAI-1 (urokinase-like plasminogen activator), whereas exhibiting functional stability less than or equal to that of WT PAI-1. Missense mutations that increase PAI-1 functional stability are concentrated in highly flexible regions within the PAI-1 structure. Finally, we developed a method for simultaneously measuring the functional half-lives of hundreds of PAI-1 variants in a multiplexed, massively parallel manner, quantifying the functional half-lives for 697 single missense variants of PAI-1 by this approach. Overall, these findings provide novel insight into the mechanisms underlying the latency transition of PAI-1 and provide a database for interpreting human PAI-1 genetic variants.

Indexed as

Plasminogen Activator Inhibitor 1SerpinsHalf-LifeHumansKineticsMutationSerine Proteinase InhibitorsPlasminogen Activator Inhibitor 1Serine Proteinase InhibitorsSerpinsenzyme inhibitorfibrinolysishigh-throughput sequencingkineticsphage displayprotease inhibitorserpin

Identifiers

PMID36257408
PMCPMC9667310
OpenAlexW4306664673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.